Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant.

Cathy Leonard Guillem Montamat GarciaCaroline DavrilOlivia DominguesOliver HunewaldDominique RevetsCoralie GuerinSimon BlankJustine HeckendornGauthier JardonFrançois HentgesMarkus Ollert

Published in: Allergy (2021)

Our results highlight the potential of CpG adjuvant in a novel formulation to be further exploited for inducing allergen-specific tolerance in patients with cat allergy or other allergic diseases.

Keyphrases

high dose
early stage
dna methylation
rheumatoid arthritis
low dose
high resolution
drug delivery
transcription factor
atopic dermatitis
gene expression
climate change
infectious diseases